Back
Top 0.6%
18.3%
Top 0.7%
9.7%
Top 60%
9.3%
Top 25%
8.1%
Top 17%
6.2%
Top 3%
5.2%
Top 2%
5.2%
Top 11%
4.0%
Top 2%
2.9%
Top 2%
2.9%
Top 2%
2.0%
Top 3%
2.0%
Top 3%
1.4%
Top 2%
1.4%
Top 14%
1.4%
Top 0.2%
1.2%
Top 5%
1.0%
Top 4%
1.0%
Top 9%
1.0%
Top 8%
1.0%
Top 2%
0.7%
Top 2%
0.7%
Top 6%
0.7%
Survival risk heterogeneity among patients with NSCLC receiving nivolumab visualized by risk scores generated from deep learning method DeepSurv using tumor gene mutations
2026-02-22
oncology
Title + abstract only
View on medRxiv
Show abstract
Immunotherapy with immune checkpoint inhibitors and immunotherapy combined with chemotherapy have represented promising treatments for NSCLC patients leading to prolonged survival. However, the majority of patients with advanced NSCLC have a poor prognosis. The identification and development of biomarkers for stratifying responders and non responders to immune checkpoint inhibitors contribute to unravel the mechanism of immune checkpoint pathway and the immune tumor interaction underlying the re...
Predicted journal destinations
1
Cancers
57 training papers
2
Frontiers in Oncology
34 training papers
3
PLOS ONE
1737 training papers
4
Scientific Reports
701 training papers
5
Nature Communications
483 training papers
6
Frontiers in Immunology
140 training papers
7
Clinical Cancer Research
22 training papers
8
eLife
262 training papers
9
Cancer Medicine
17 training papers
10
iScience
74 training papers
11
BMC Cancer
21 training papers
12
British Journal of Cancer
22 training papers
13
Diagnostics
36 training papers
14
Frontiers in Pharmacology
27 training papers
15
npj Digital Medicine
85 training papers
16
PNAS Nexus
22 training papers
17
PeerJ
46 training papers
18
International Journal of Molecular Sciences
39 training papers
19
Heliyon
57 training papers
20
Computers in Biology and Medicine
39 training papers
21
Aging
18 training papers
22
Cell Reports
25 training papers
23
Communications Medicine
63 training papers